2024年 DEA大麻再定時決定が延期され,市場が衰退し,株価が下がった. 2024 DEA cannabis rescheduling ruling delayed, causing market downturn and stock declines.
米国薬物規制局 (DEA) は,大麻の再定行に関する最終決定を2024年大統領選挙以降に延期し,大麻セクターの市場の低迷と,Curaleaf Holdings,Cresco Labs,Cansortiumなどの大麻株の大幅な減少を引き起こした. The U.S. Drug Enforcement Administration (DEA) delayed its final ruling on cannabis rescheduling until after the 2024 presidential election, causing a market downturn in the cannabis sector and significant declines in major cannabis stocks like Curaleaf Holdings, Cresco Labs, and Cansortium. DEAは2024年12月に行政法判事 (ALJ) の公聴会を予定しており,市場の不確実性を高めています. The DEA set an Administrative Law Judge (ALJ) hearing for December 2024, increasing market uncertainty. 投資家は大麻株価の潜在的下落に備え 投資決定する前にリスクと利益について検討する必要があります Investors should be prepared for potential downturns in cannabis stock prices and consider risks and rewards before making investment decisions. 2024年の選挙の結果は 大麻の再定行と産業の将来に大きな影響を与えます The outcome of the 2024 election will significantly impact cannabis rescheduling and the future of the industry.